2023.03.07
I-Mab Receives “A” Rating in Updated MSCI ESG Assessment
I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
2023.03.07
I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.
2022.11.03
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.
2022.10.05
I-Mab will present new preclinical data of its core assets lemzoparlimab and uliledlimab at the 37th SITC Annual Meeting.
2022.09.13
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
2022.09.10
I-Mab today announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed HR-MDS.
2022.09.06
I-Mab today announced that the results from its Phase 2 clinical study of lemzoparlimab in combination with azacitidine in patients with HR-MDS will be featured in a proffered paper presentation at the upcoming ESMO Congress 2022.
2022.08.30
I-Mab today announced financial results for the six months ended June 30, 2022, and provided key business updates.
2022.08.23
I-Mab today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.
2022.08.19
I-Mab will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022.
2022.07.22
I-Mab today announced that the first patient in China has been treated with TJ-CD4B in a Phase 1 IMCT for patients with solid tumors.